enGene (NASDAQ:ENGN) Releases Quarterly Earnings Results, Hits Estimates

enGene (NASDAQ:ENGN) posted its earnings results on Tuesday. The company reported ($0.47) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.47), FiscalAI reports.

enGene Stock Performance

NASDAQ ENGN opened at $1.82 on Tuesday. The firm has a market cap of $121.92 million, a P/E ratio of -0.84 and a beta of -0.28. The company has a debt-to-equity ratio of 0.10, a current ratio of 12.57 and a quick ratio of 12.57. The stock’s 50-day moving average is $1.82 and its 200-day moving average is $4.11. enGene has a one year low of $1.40 and a one year high of $12.25.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of enGene in a research report on Wednesday, August 12th. Morgan Stanley cut shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective for the company. in a report on Thursday, June 18th. UBS Group lowered their target price on shares of enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of enGene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, HC Wainwright reduced their price target on shares of enGene from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Four equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $11.05.

Institutional Trading of enGene

A number of large investors have recently bought and sold shares of the business. Cresset Asset Management LLC acquired a new stake in enGene during the 2nd quarter worth approximately $36,000. Paloma Partners Management Co acquired a new position in shares of enGene in the second quarter valued at approximately $38,000. Raymond James Financial Inc. boosted its holdings in shares of enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after buying an additional 7,932 shares during the period. Jump Financial LLC bought a new stake in shares of enGene during the fourth quarter worth $121,000. Finally, Millennium Management LLC increased its position in shares of enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after acquiring an additional 7,472 shares in the last quarter. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.